Abstract:The article contains the results of a comparison pharmacoeconomical cost-utility analysis of several options for dual antiplatelet therapy in patients with acute coronary syndrome after stent implanting. The costs for treatment alternatives with and without prior pharmacogenetic testing for CYP2C19 were calculated. According to the results of the analysis the most cost-effective treatment option for patients with acute coronary syndrome is prior pharmacogenetic testing and the choice of the antiplatelet drug p… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.